So far we (AVXL) have been the driver determining when trial/other PR-news releases happen. We may eventually be behind on events as in trial news/partner-deal news, trash like suites news, etc. The work AVXL is doing is mega news stuff, much bigger than we are in scope and impact. So, pick your poison b/c the pace of life will change. I am looking forward to it myself.
Thanks for the “TBT” webcast Kevli. Im not sure I caught that one the first time around. Some presentations get published and others dont. Interesting how they are honing in on who will be predisposed to Nuero diseases. For example the val66 gene is found in %33 of both Rett and Alz patients and leads to cognitive decline.”Additional layers” are being added studying our Ph 2a in a reverse engineering fashion. As some here have commented on our German CEO is over designing our ph2b/3 trial setting it up for success in a possible overwhelming manner. In 5 years (with the use of AI)we will all look back at this antiquated but historical approach and really only then will we truly appreciate our leaderships approach in its entirety.
News 
Market Data 
Discover 
